RT Journal Article
SR Electronic
T1 Association of Gout with Brain Reserve and Vulnerability to Neurodegenerative Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.09.22282119
DO 10.1101/2022.11.09.22282119
A1 Topiwala, Anya
A1 Mankia, Kulveer
A1 Bell, Steven
A1 Webb, Alastair
A1 Ebmeier, Klaus P
A1 Howard, Isobel
A1 Wang, Chaoyue
A1 Alfaro-Almagro, Fidel
A1 Miller, Karla
A1 Burgess, Stephen
A1 Smith, Stephen
A1 Nichols, Thomas E
YR 2022
UL http://medrxiv.org/content/early/2022/11/13/2022.11.09.22282119.abstract
AB Objectiv To assess the associations between gout, brain structure, and neurodegenerative disease incidence.Methods Using observational and Mendelian randomization analyses we investigated causal relationships between gout and brain health. Exposures included gout diagnosis (from self-report, linked health records and death records) and genetically proxied gout and serum urate. Outcomes were neuroimaging markers of brain structure and neurodegenerative disease incidence (ascertained through self-report, health records and death reports). Cox proportional hazards models were used to examine time to neurodegenerative disease diagnosis.Results 11,735 UK Biobank participants (mean age 55.5±8.0 years and 50.5% female) had a diagnosis of gout (n=1165 in MRI subset). Dementia was ascertained in 3126 individuals over a mean follow-up time of 12.4±1.9 years. Gout patients had smaller global and regional brain volumes and higher brain iron markers. Genetic associations mirrored observational associations. Genetically proxied gout associated with lower global grey matter volume (beta= -0.05[-0.08 to -0.01]). Participants with gout had higher incidence of all-cause dementia (hazard ratio (HR)=1.60, 95% confidence interval (CI) [1.38-1.85]), Parkinson’s disease (HR=1.43[1.15 to 1.79]), and probable essential tremor (HR=6.75[5.69 to 8.00]). Risks were strongly time dependent, whereby associations with incident dementia were highest in the first 3 years after gout diagnosis (HR=7.40[4.95 to 11.07]).Conclusions These findings suggest gout is causally related to several measures of brain structure. Lower brain reserve amongst gout patients may explain their higher vulnerability to multiple neurodegenerative diseases.What is already known on this topic?Studies of neurodegenerative disease risk in gout are contradictory.Relationships with neuroimaging markers of brain structure, which may offer insights, are uncertain.What this study adds?In this prospective cohort study gout was associated with smaller brain volumes and higher incidence of multiple neurodegenerative diseases.Mendelian randomization analyses suggested gout is causally related to brain structure.How might this study affect research, practice or policy?Our findings emphasise the importance for clinicians of assessing for motor and cognitive impairments amongst gout patients, particularly in early years after diagnosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAT is supported by a Wellcome Trust (https://wellcome.org/) fellowship (216462/Z/19/Z).KPE is funded by the UK Medical Research Council (https://mrc.ukri.org/, G1001354 & MR/K013351/1) and the European Commission (https://ec.europa.eu/programmes/horizon2020/en/home, Horizon 2020 732592). SBu is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (https://royalsociety.org/, 204623/Z/16/Z). SBe was supported by the British Heart Foundation (https://www.bhf.org.uk/for-professionals/information-for-researchers/what-we-fund, RG/16/4/32218) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). SS is supported by a Wellcome Trust Collaborative Award 215573/Z/19/Z. KLM is supported by a Wellcome Trust Senior Research Fellowship (202788/Z/16/Z). TN is supported by the Li Ka Shing Centre for Health Information and Discovery, an NIH grant (https://www.nih.gov/, TN: R01EB026859), the National Institute for Health Research Oxford Biomedical Research Centre (BRC-1215-20014), and a Wellcome Trust award (TN: 100309/Z/12/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UKB has ethics committees approvalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the present study are available upon successful UKB application or publically available summary statistics